Literature DB >> 16391404

Intravenous immunoglobulin for treatment of pemphigus.

Lehavit Akerman1, Daniel Mimouni, Michael David.   

Abstract

Pemphigus is a group of organ-specific, autoimmune, mucocutaneous blistering disorders with an established immunological basis. The goal of therapy in pemphigus is to eliminate or neutralize the pathogenic autoantibodies. As in other autoimmune diseases, early systemic therapy is important for control of the disease and for achieving sustained remissions. Because of the sparse number of controlled studies, the treatment of autoimmune bullous diseases remains controversial. In this article, we discuss the current therapeutical options in pemphigus with an emphasis on IVIg treatment and suggest guidelines for the use of IVIg in the treatment of pemphigus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16391404     DOI: 10.1385/CRIAI:29:3:289

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  34 in total

1.  Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins.

Authors:  G G Tóth; M F Jonkman
Journal:  Br J Dermatol       Date:  1999-09       Impact factor: 9.302

2.  In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations--a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases.

Authors:  I Krause; R Wu; Y Sherer; M Patanik; J B Peter; Y Shoenfeld
Journal:  Transfus Med       Date:  2002-04       Impact factor: 2.019

3.  Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.

Authors:  A R Ahmed
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

Review 4.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 5.  Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?

Authors:  Yolanda Braun-Moscovici; Daniel E Furst
Journal:  Curr Opin Rheumatol       Date:  2003-05       Impact factor: 5.006

6.  The course and prognosis of pemphigus. A review of 115 patients.

Authors:  M Seidenbaum; M David; M Sandbank
Journal:  Int J Dermatol       Date:  1988-10       Impact factor: 2.736

7.  Dexamethasone-cyclophosphamide pulse therapy for pemphigus.

Authors:  J S Pasricha; B K Khaitan; R S Raman; M Chandra
Journal:  Int J Dermatol       Date:  1995-12       Impact factor: 2.736

8.  Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins.

Authors:  Susanne Herzog; Enno Schmidt; Matthias Goebeler; Eva-B Bröcker; Detlef Zillikens
Journal:  Acta Derm Venereol       Date:  2004       Impact factor: 4.437

9.  Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies.

Authors:  I Lundkvist; P A van Doorn; M Vermeulen; A Brand
Journal:  Clin Immunol Immunopathol       Date:  1993-06

10.  Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.

Authors:  F Rossi; D R Jayne; C M Lockwood; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.